Guggenheim Capital LLC Boosts Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Guggenheim Capital LLC lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 133.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 48,131 shares of the company's stock after buying an additional 27,518 shares during the period. Guggenheim Capital LLC's holdings in Denali Therapeutics were worth $981,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Sterling Capital Management LLC increased its holdings in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after purchasing an additional 885 shares during the last quarter. KBC Group NV grew its holdings in Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after purchasing an additional 2,731 shares during the last quarter. AlphaQuest LLC grew its holdings in Denali Therapeutics by 177.1% during the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock valued at $142,000 after purchasing an additional 4,449 shares during the last quarter. Finally, E Fund Management Co. Ltd. grew its holdings in Denali Therapeutics by 32.2% during the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Stock Up 3.6 %

Shares of NASDAQ DNLI traded up $0.57 during trading hours on Monday, hitting $16.25. 1,423,906 shares of the stock were exchanged, compared to its average volume of 1,080,009. The company has a market cap of $2.36 billion, a PE ratio of -5.89 and a beta of 1.58. The firm has a fifty day moving average price of $14.85 and a 200-day moving average price of $20.71. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. As a group, equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on DNLI. William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Thursday. B. Riley reissued a "buy" rating and issued a $35.00 price objective (down from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. HC Wainwright boosted their price objective on shares of Denali Therapeutics from $80.00 to $87.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, The Goldman Sachs Group lowered their price objective on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $37.57.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.